This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E71.1 (other disorders of branched-chain amino-acid metabolism) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | IVA, Isovaleryl-CoA dehydrogenase deficiency, IVD deficiency, isovaleric aciduria, sweaty feet syndrome |
| C. Adult onset | Likelihood of first onset in adulthood low (possible for the mild phenotype) — the classic form presents in the neonatal period to infancy; the mild/asymptomatic form (mild IVA) found after tandem mass screening can remain asymptomatic into adulthood. |
| 1. History | 1966, first described by Tanaka and Rosenberg (sweaty-odor urine + ketoacidosis) → 1970s, IVD enzyme deficiency identified → 1980s, glycine supplementation therapy introduced → 2000s, mild phenotype discovered after tandem mass screening. |
| 2. Causes | IVD gene (15q14-q15) mutation → isovaleryl-CoA dehydrogenase (IVD) deficiency → block at step 3 of leucine metabolism → accumulation of isovaleryl-CoA, isovaleric acid and 3-hydroxyisovaleric acid. |
| 3. Genetics | Autosomal recessive. IVD gene (15q14-q15). c.932C>T (p.Ala282Val) polymorphism: a cause of false-positive screening. Worldwide about 1/67,000–1/250,000. Proportion of mild cases increased in Korea after tandem mass screening. |
| 4. General epidemiology | Worldwide about 1/67,000–250,000. Males and females equally. After tandem mass screening, mild/biochemical forms without clinical symptoms increased to about 50% of the total. Korea: included in tandem mass screening, a few patients per year. |
| 5. Pathophysiology | IVD deficiency → isovaleryl-CoA accumulation → impaired mitochondrial function, conjugation with glycine (isovalerylglycine), conjugation with carnitine (C5-carnitine) → ketoacidosis and hyperammonemia; direct neurotoxicity of isovaleric acid. |
| 6. Symptoms | Classic form: neonatal ketoacidosis, hyperammonemia, characteristic sweaty feet odor (isovaleric acid) + lethargy and poor feeding. Chronic intermittent form: acute metabolic crisis during catabolism. Mild/asymptomatic form: incidental finding on tandem mass. |
| 7. Signs | Elevated C5-acylcarnitine (isovalerylcarnitine), increased urinary isovalerylglycine, increased urinary 3-hydroxyisovaleric acid, metabolic ketoacidosis, hyperammonemia, pancytopenia. |
| 8. Screening | Newborn tandem mass screening (elevated C5-acylcarnitine). Caution: false positives for the mild form due to the c.932C>T polymorphism are frequent. Urine organic acid analysis (isovalerylglycine) + IVD gene testing essential for confirmation. Included in Korean national screening. |
| 9. Diagnosis | Plasma C5-acylcarnitine, urine organic acids (isovalerylglycine, 3-OH-isovaleric acid), IVD enzyme activity (fibroblasts), IVD gene NGS. Differentiation of C5/C5-acylcarnitine from MSUD needed. |
| 10. Treatment | Glycine supplementation (promotes detoxification as isovalerylglycine, 150–600 mg/kg/day) + L-carnitine supplementation + low-leucine (low-protein) diet. Acute phase: glucose administration to suppress catabolism. Mild form: minimal restriction or normalized diet. |
| 11. Prognosis | Good prognosis even for the classic form with early treatment (intellectual disability rare). Normal prognosis for the mild/asymptomatic form. Normal life expectancy if managed without recurrent metabolic crises. Fewer neurologic and renal complications than other organic acidemias. |
| 12. Prevention | Newborn tandem mass screening, genetic counseling, PGT-M. Affected individuals: emergency protocol for catabolic stress (sufficient energy + temporary protein restriction), vaccination to prevent infection, continued glycine and carnitine supplementation. |
| 13. References | Tanaka K et al. Isovaleric acidemia: a new genetic defect of leucine metabolism. Proc Natl Acad Sci USA. 1966;56:236-242 … and 9 other papers |
Isovaleric acidemia (IVA) was first described in 1966 when the American biochemists Danika Tanaka, Leon Rosenberg and colleagues reported cases with recurrent metabolic ketoacidosis in the neonatal period and urine with a characteristic sweaty feet odor. Using gas chromatography, they identified isovaleric acid in the patients' urine and confirmed that isovaleric acid excretion increased markedly with an oral leucine load, revealing that an abnormality of leucine metabolism was the cause. This discovery is regarded as a pioneering achievement in organic acidemia research.
In the 1970s, deficient activity of isovaleryl-CoA dehydrogenase (IVD) was identified as the causative enzyme defect of IVA. This enzyme is located in the mitochondria and, using flavin adenine dinucleotide (FAD) as a cofactor, catalyzes the oxidation of isovaleryl-CoA, the third step of leucine metabolism. In 1984, Stader et al. purified and characterized the IVD enzyme, and the IVD gene (15q14-q15) was subsequently cloned in the 1990s.
The most important milestone in treatment development was the introduction of glycine supplementation therapy in the late 1970s to early 1980s. William et al. and Nyhan et al. discovered that glycine conjugates with isovaleryl-CoA, converting it to the less toxic isovalerylglycine, which is excreted in urine, thereby reducing the accumulation of isovaleric acid in the body. It was later shown that L-carnitine supplementation also contributes to strengthening the detoxification pathway through excretion of isovalerylcarnitine. These two supplementation therapies have now become the core of long-term management of IVA.
Since the 2000s, with the introduction of tandem mass screening in newborn screening, an unexpected and important discovery was made in IVA. It was confirmed that individuals homozygous for c.932C>T (p.Ala282Val), a common variant of the IVD gene, or a similar mild variant show elevated C5-acylcarnitine but often have no or very mild clinical symptoms. This phenotype, classified as so-called "mild IVA" or "biochemical IVA", now accounts for about half of all IVA patients found by tandem mass screening, and controversy continues over whether they belong to the same disease group as true IVA and whether treatment is needed.
In Korea as well, since the introduction of national tandem mass newborn screening in 2006, patients with IVA have been detected early, and discussions on distinguishing the mild and classic forms and on the need for treatment are taking place in Korea too. Most recently, in 2025, a systematic literature review and expert consensus guideline on the diagnosis and management of IVA were published, establishing the latest clinical evidence.
Isovaleric acidemia is an organic acidemia of abnormal leucine metabolism caused by functional deficiency of the mitochondrial enzyme isovaleryl-CoA dehydrogenase (IVD, EC 1.3.8.1). IVD is the enzyme that catalyzes the third step in the mitochondrial degradation pathway of leucine, responsible for the dehydrogenation (oxidation) of isovaleryl-CoA to 3-methylcrotonyl-CoA. This reaction involves the transfer of electrons via FAD to electron transfer flavoprotein (ETF).
When IVD enzyme activity is deficient due to pathogenic mutations of the IVD gene (15q14-q15), isovaleryl-CoA accumulates and generates toxic metabolites through the following pathways. (1) Hydrolysis to isovaleric acid: the substance responsible for the characteristic sweaty feet odor, detected in blood, urine and breath. (2) Conjugation with glycine forms isovalerylglycine (IVG): IVG has low toxicity and is excreted in urine; this pathway is a natural detoxification mechanism and the rationale for therapeutic glycine supplementation. (3) Conjugation with carnitine forms isovalerylcarnitine (C5-AC): detected in urine and blood, and the main marker in tandem mass screening. (4) 3-Hydroxyisovaleric acid: a product of an alternative oxidation pathway of isovaleryl-CoA, increased in urine.
The phenotypic heterogeneity of IVA is associated with residual IVD enzyme activity. Complete loss-of-function mutations (premature stop codon, frameshift, etc.) are associated with the classic form (classic IVA), and partial loss-of-function mutations (especially c.932C>T/p.Ala282Val) are associated with the mild form. In particular, c.932C>T only slightly impairs folding of the IVD enzyme protein, so some residual enzyme activity is often preserved, and clinical symptoms are often mild or absent.
Isovaleric acidemia follows autosomal recessive inheritance. The causative gene IVD is located on the long arm of chromosome 15 (15q14-q15) and encodes the IVD protein, including a mitochondrial targeting signal sequence. The IVD gene consists of 12 exons, and dozens of pathogenic variants have been reported to date.
In terms of genotype, a particularly notable variant is c.932C>T (p.Ala282Val), which has the following unique characteristics. (1) When this variant is homozygous, C5-acylcarnitine is measured high on newborn tandem mass, giving a positive IVA screen, but clinical symptoms are absent or very mild, making it difficult to regard these individuals as true IVA patients. (2) Because the allele frequency of this variant is relatively high (in some populations, more than 1 in several thousand people is a heterozygous carrier), it causes false positives for IVA and overdiagnosis of the mild form in tandem mass screening. (3) Therefore, experts are still debating whether this variant should be regarded as a "clinically meaningful pathogenic variant" or a "low-penetrance polymorphism". The IVA diagnosis and management guideline published in 2025 recognizes mild IVA as a separate phenotype and recommends approaching it distinctly from the classic form. Other variants associated with severe phenotypes that have been reported include missense variants such as p.R363C and p.R441H as well as nonsense and frameshift variants.
The worldwide prevalence of isovaleric acidemia is estimated at about 1/67,000–1/250,000 based on tandem mass screening data, varying by region and screening criteria. Before the introduction of tandem mass screening, it was diagnosed only when symptoms appeared, but after its introduction many c.932C>T homozygous individuals were included, increasing the apparent prevalence. Some studies report that about half of IVA patients found by tandem mass screening are classified as the mild/asymptomatic form.
Given autosomal recessive inheritance, the sex distribution is equal. Reports of concentrated high prevalence in specific ethnic groups or regions are not as prominent as for PA and MMA. In Korea, IVA has been included in national tandem mass newborn screening since 2006, and a few patients are diagnosed early each year, with mild and classic forms mixed. The number of registered patients in Korea is estimated at several dozen. Before tandem mass screening, some patients with classic IVA died without being diagnosed in the neonatal period, or were diagnosed after recurrent metabolic crises with complications such as intellectual disability. Today, with early detection through screening and glycine and carnitine supplementation, normal or near-normal development is possible in most patients.
The core pathogenesis of isovaleric acidemia is intramitochondrial accumulation of isovaleryl-CoA due to IVD enzyme deficiency and secondary toxic mechanisms. IVD catalyzes the conversion of isovaleryl-CoA to 3-methylcrotonyl-CoA in the leucine catabolism pathway, and when this reaction is blocked, isovaleryl-CoA accumulates.
Direct toxicity: when isovaleryl-CoA accumulates in the mitochondria, it (1) inhibits N-acetylglutamate (NAG) synthesis, suppressing the urea cycle and causing hyperammonemia, (2) inhibits the glycine cleavage system (GCS), resulting in hyperglycinemia and (3) disrupts energy metabolism by inhibiting mitochondrial complex activity. Toxicity of isovaleric acid: isovaleric acid, which is highly membrane-permeable (and can move in gaseous form), is directly toxic to neurons and is reported to disrupt GABAergic and glutamatergic synapses of neurotransmitters at high concentrations. This may be related to the mechanism of seizures and impaired consciousness. Detoxification pathways: isovaleryl-CoA (1) forms isovalerylglycine (IVG) with glycine via N-acyl transfer (acyl transferase) and is excreted in urine, or (2) conjugates with carnitine to form isovalerylcarnitine (C5-AC), which is excreted in urine. These two pathways are natural detoxification mechanisms that excrete isovaleryl-CoA from the body into the urine. Glycine and carnitine supplementation work on the principle of strengthening these pathways to reduce accumulation of isovaleryl-CoA in the body. Secondary carnitine deficiency: when formation and excretion of isovalerylcarnitine continue, free carnitine in the body is depleted, causing secondary carnitine deficiency, which worsens energy deficit through impaired long-chain fatty acid oxidation.
The clinical symptoms of isovaleric acidemia differ greatly by phenotype and are divided into the classic form (classic IVA) and the mild/asymptomatic form (mild/biochemical IVA).
Neonatal symptoms of classic IVA: symptoms begin within 3–14 days after birth. The most characteristic feature is a distinctive sweaty feet odor from the urine, earwax, sweat and breath, caused by isovaleric acid. Poor feeding, lethargy, vomiting and hypotonia appear early and rapidly progress to metabolic ketoacidosis, hyperammonemia, seizures and coma. Without treatment, death can occur in the neonatal period. When blood ammonia is markedly elevated, there is a risk of brain injury.
Chronic intermittent IVA: shows an intermittent course after a neonatal acute crisis or from the outset. When catabolic stress such as fever, infection, surgery or fasting occurs, acute metabolic crises present with sudden vomiting, lethargy, ataxia, ketoacidosis and the characteristic odor. Between episodes, near-normal life is possible, and development is often relatively normal.
Mild/asymptomatic IVA: found by elevated C5-acylcarnitine on newborn tandem mass screening, but clinical symptoms are absent or very mild. This phenotype appears mainly in individuals homozygous for c.932C>T or compound heterozygous (including a mild variant). Long-term follow-up studies are confirming that their neurodevelopment is generally normal. Some may show mild metabolic abnormalities under catabolic stress, but these differ from the serious crises of classic IVA.
Biochemical test findings: (1) Elevated plasma/urine C5-acylcarnitine (isovalerylcarnitine): the most specific tandem mass screening marker for IVA. It must be differentiated from the C5 branched-chain acylcarnitine seen in MSUD, which is possible with precise tandem mass and urine organic acid analysis. (2) Urine organic acid analysis (GC-MS): a marked increase in isovalerylglycine (IVG) is the most specific diagnostic marker of IVA. IVG is detected only in trace amounts in healthy people but rises to tens to hundreds of mmol/mol Cr in patients with IVA. 3-Hydroxyisovaleric acid is also increased. (3) Metabolic ketoacidosis (low pH, increased anion gap) and hyperammonemia appear in the acute phase. (4) Reduced blood free carnitine and increased acylcarnitine ratio. (5) Pancytopenia (bone marrow suppression) can occur after recurrent metabolic crises.
Clinical signs: the characteristic sweaty feet odor (odor of isovaleric acid) is strongly noticeable around the patient in the acute phase and is an important clinical clue for the medical team and caregivers. In the mild/asymptomatic form, physical examination and test findings are mostly normal, and often only a mild elevation of C5-acylcarnitine on incidentally performed tandem mass testing is found. Brain MRI may show basal ganglia signal abnormalities after acute metabolic crises, but less frequently than in PA or MMA.
Isovaleric acidemia is a major target disease of newborn tandem mass screening and is included in the Korean national newborn screening program. The screening marker is elevated C5-acylcarnitine (isovalerylcarnitine). Because C5-AC is sometimes labeled with the same name as 2-methylbutyrylcarnitine (short/branched chain acylcarnitine, elevated in MSUD screening), it is important to distinguish the two peaks with precise tandem mass (MRM method).
The most important clinical issue in IVA screening is the problem of false positives or overdiagnosis of the mild form due to the mild form occurring in individuals homozygous for c.932C>T (p.Ala282Val). These mildly affected individuals have slightly elevated C5-AC but are often clinically unaffected, which can lead to unnecessary treatment and family anxiety. To minimize this, the confirmation process for screen-positive newborns must include urine organic acid analysis (confirming IVG excretion) and IVD gene testing. Current guidelines emphasize strictly applying post-screening confirmation criteria to distinguish the classic form from the mild form and ensuring that unnecessary treatment, such as excessive dietary restriction, is not given in the mild form.
Isovaleric acidemia is confirmed by integrating clinical findings, biochemistry and molecular genetics. (1) Tandem mass acylcarnitine analysis: confirmation of elevated C5-acylcarnitine. (2) Urine organic acid analysis (GC-MS): a marked increase in isovalerylglycine (IVG) is the most specific diagnostic marker of IVA. 3-Hydroxyisovaleric acid is also increased. Differentiation from 2-methylbutyrylglycine (an MSUD marker) is needed. (3) Plasma amino acid analysis: elevated glycine observed in some. (4) IVD enzyme activity measurement: measured in skin fibroblasts or leukocytes. Less than 5% of normal in the classic form, 10–30% in the mild form. (5) IVD gene NGS testing: confirmation of pathogenic variants and subtype classification. When c.932C>T homozygosity is confirmed, the possibility of the mild form is considered. (6) Differential diagnosis: 2-methylbutyrylglycinuria (short/branched chain acyl-CoA dehydrogenase deficiency, SBCAD) — shares elevated C5-AC but is distinguished by excretion of 2-methylbutyrylglycine instead of IVG; 3-methylcrotonyl-CoA carboxylase deficiency (3-MCC deficiency) — different urine organic acid profile; MSUD — distinguished by elevated leucine and alloisoleucine. (7) After classic IVA is confirmed, cardiac evaluation (ECG, echocardiography) and brain MRI are performed as needed to assess complications.
Treatment of isovaleric acidemia varies by phenotype and is divided into acute-phase treatment and long-term maintenance treatment.
Treatment of acute metabolic crisis: (1) Temporary cessation of leucine intake: protein intake is stopped for 24–48 hours to cut off the raw material for isovaleryl-CoA production. (2) Sufficient energy supply: high-calorie, glucose-based supply suppresses endogenous protein catabolism. Replaced by parenteral nutrition when oral intake is impossible. (3) High-dose glycine: glycine 250–600 mg/kg/day is given orally or parenterally to maximize isovalerylglycine formation and promote excretion of toxic metabolites. (4) Intravenous L-carnitine: promotes isovalerylcarnitine excretion and replenishes carnitine. (5) Management of hyperammonemia (N-carbamylglutamate, sodium benzoate).
Long-term maintenance treatment: (1) Leucine-restricted low-protein diet: special formula (including a leucine-restricted amino acid mixture) or low-protein diet based on the principle of providing the minimum leucine needed for growth and development. Because excessive protein restriction causes growth impairment and essential amino acid deficiency, individualized adjustment with monitoring of nutritional status is needed. (2) Glycine supplementation (150–300 mg/kg/day): strengthens the isovalerylglycine formation pathway, continuously promoting excretion of toxic metabolites. Glycine supplementation is relatively safe, and long-term use is recommended especially in patients with classic IVA. (3) L-carnitine supplementation (50–100 mg/kg/day): prevents secondary carnitine deficiency and promotes isovalerylcarnitine excretion. (4) Mild/asymptomatic form: there is controversy over the need for treatment, but the latest guidelines tend to recommend only minimal management, such as clinic follow-up or education on the emergency protocol. Excessive leucine-restricted diet and glycine supplementation may be unnecessary in the mild form. Preventive measures during catabolic stress (high energy supply, temporary protein restriction) are recommended for both the classic and mild forms.
Isovaleric acidemia is regarded as having a relatively good prognosis among the organic acidemias. Even in classic IVA, with appropriate glycine and carnitine supplementation and dietary management from the neonatal period, normal or near-normal intellectual and physical development is possible. According to long-term follow-up studies, the cognitive function of patients with IVA who received early treatment often shows a normal distribution without significant difference from controls. This reflects the relatively good prognosis of IVA in that neurologic and renal complications are markedly fewer than in PA or MMA.
Most patients with the mild/asymptomatic form lead normal lives even without treatment. However, it is important to educate patients and families about the possibility of metabolic crises during catabolic stress. In patients who have experienced recurrent acute metabolic crises, neurologic sequelae such as intellectual disability, developmental delay and dyskinesia may develop. Life expectancy is close to normal when early detection and appropriate treatment are achieved. Data on the lives and pregnancies of adult patients with IVA are also accumulating, and specialist guidance on metabolic management during pregnancy in female patients with IVA is needed.
Primary prevention of isovaleric acidemia is achieved through genetic counseling and preimplantation/prenatal genetic testing. With two carrier parents, there is a 25% chance of an affected child with IVA in each pregnancy, and PGT-M through IVD gene analysis or prenatal DNA testing (chorionic villus sampling or amniocentesis) is possible. Carrier testing is best performed in families that already have a child with IVA before planning the next pregnancy.
As secondary prevention in affected patients, early diagnosis through newborn tandem mass screening with immediate confirmation, followed by phenotype classification (classic vs mild) and establishment of an appropriate treatment plan, is key. In patients with the classic form, because catabolic stress (fever, infection, fasting, surgery) is the main trigger of acute metabolic crises, they are educated to immediately carry out a prepared emergency protocol (increased glycine and carnitine, temporary protein restriction, sufficient energy supply) and to always carry an emergency card. Reducing the frequency of fever and infection through pneumococcal and influenza vaccination also indirectly helps prevent metabolic crises. Glycine and L-carnitine supplementation is maintained routinely to strengthen metabolite excretion pathways. It is recommended to build a multidisciplinary management system (inherited metabolic disease specialist, dietitian, neurology, pediatrics) that detects complications early and continuously optimizes the treatment plan through regular monitoring of plasma amino acids and C5-acylcarnitine, nutritional assessment and developmental follow-up.